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What is already known about this topic? 35 
Clinical trials provide no evidence to support recommendations that children with asthma 36 
prescribed long-acting β2-agonist (LABA) should receive treatment as a fixed-dose 37 
combination inhaler and not by addition of a separate inhaler to inhaled corticosteroids (ICS).  38 
What does this article add to our knowledge?  39 
In a matched cohort study, LABA treatment as a separate inhaler was associated with poorer 40 
asthma control and increased risk for exacerbation compared to fixed-dose combination 41 
inhaler. 42 
How does this study impact current management guidelines? 43 
These findings support British Thoracic Society, NICE asthma guideline and Food and US 44 
Drug Administration recommendations to prescribe add-on LABA as a fixed-dose combination 45 
inhaler with ICS in children 46 
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ABSTRACT  48 
Background Adding a long-acting β2-agonist (LABA) to inhaled corticosteroids (ICS) using a 49 
fixed-dose combination (FDC) inhaler containing ICS and LABA is the UK guideline-50 
recommended step-up option for children aged >4 years with uncontrolled asthma on ICS 51 
monotherapy. The evidence of benefit of FDC inhalers over adding a separate LABA inhaler 52 
to ICS therapy is limited.  53 
Objective: Our aim was to compare outcomes for FDC versus separate LABA+ICS inhalers 54 
for children by analyzing routinely-acquired clinical and prescribing data. 55 
Methods This matched cohort study used large UK primary care databases to study children 56 
prescribed their first step-up from ICS monotherapy at 5–12 years of age as add-on LABA, 57 
either via separate LABA inhaler or FDC inhaler. A baseline year was examined to 58 
characterize patients and identify potential confounders; outcomes were examined during the 59 
subsequent year. The primary outcome was adjusted odds ratio for overall asthma control, 60 
defined as no asthma-related hospital admission, emergency room visit prescription for oral 61 
corticosteroids and ≤200 μg/day salbutamol. 62 
Results After matching, there were 1330 children in each cohort (mean age [SD] 9 [2] years; 63 
59% male). All measures of asthma exacerbations and control improved during the outcome 64 
year in both cohorts. In the separate ICS+LABA cohort, the odds of achieving overall asthma 65 
control were lower (adjusted odds ratio, 0.77 [95% CI 0.66-0.91] P = 0.001) compared with 66 
the FDC cohort.   67 
Conclusion Our results demonstrate a small but significant benefit of add-on LABA therapy 68 
as FDC over separate inhaler and support current recommendations. 69 
 70 
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INTRODUCTION 72 
Asthma is common amongst children in the UK, with an estimated 8%, or 1.1 million children, 73 
prescribed current asthma therapy.1,2 The British Thoracic Society and Scottish Intercollegiate 74 
Guidelines Network (BTS/SIGN) guideline for the management of asthma recommends a 75 
stepwise approach to therapy to maintain symptom control and minimize future risk of 76 
exacerbations. Inhaled corticosteroids (ICS), prescribed at step 2 of the current BTS/SIGN 77 
guideline, are effective controller medications for most children with persistent asthma, 78 
although from 10–25% of children require additional therapy.3-6 Adding a long-acting β2-79 
agonist (LABA) to ICS is the preferred step-up option (step 3) recommended by the BTS/SIGN 80 
for children ages 5–12 years with uncontrolled asthma on ICS monotherapy.3 81 
 Guidance from the UK National Institute for Health and Care Excellence (NICE) 82 
identifies a fixed-dose combination (FDC) inhaler containing ICS and LABA as the optimal 83 
means of adding a LABA, preferred over adding LABA as a separate inhaler,2 but some 84 
children continue to be prescribed separates. One risk of prescribing LABA as a separate 85 
inhaler is its use without concomitant ICS therapy, and the National Review of Asthma Deaths 86 
recommended that LABA “should be prescribed with an inhaled corticosteroid in a single 87 
combination inhaler”.7 88 
The benefit of FDC over addition of separate LABA inhaler to ICS treatment for children 89 
with asthma is unclear. Two clinical trials, where adherence was closely monitored, found no 90 
difference in symptoms after 38 and 6 months’9 treatment between groups randomized to 91 
LABA as separate inhaler or FDC. However, patient behaviours and clinical outcomes are 92 
often different in the context of a clinical trial as opposed to ‘real-life’ usual clinical care. One 93 
database study observed reduced need for short-acting β2-agonist (SABA) and oral 94 
corticosteroid treatment in children treated with LABA as an FDC compared with additional 95 
inhaler,4 but importantly there was no matching at baseline for factors known to be different 96 
between groups, including age and obesity.10 We have recently reported that children stepped 97 
up to LABA as a separate inhaler are younger and on a lower dose of ICS compared with 98 
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those stepped up to FDC,10 and these baseline differences might explain the apparent 99 
superiority of FDC over LABA as separate inhaler.   100 
Rigorously conducted observational research can provide information about outcomes 101 
of asthma therapy under conditions of usual clinical practice to complement information from 102 
controlled trials.11 Results of prior retrospective observational studies suggest that adherence 103 
and refill persistence may be better with a combination inhaler, at least among adults and 104 
adolescents.12-14 In turn, better adherence and persistence could lead to better outcomes. The 105 
aim of this large population-based observational study was to evaluate whether outcomes 106 
differ between children with asthma stepped up to add-on LABA as separate vs. FDC inhalers. 107 
Our hypothesis was that children stepped up to separate inhalers would have increased odds 108 
for poor asthma control compared with matched children stepped up to FDC. 109 
  110 
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METHODS 111 
Data source and permissions 112 
In a matched cohort study, we sourced medical record and prescribing data from two large 113 
primary care databases including ~15% of children in the UK, as previously described.10 114 
Duplicate records from individual children were identified and removed. The Clinical Practice 115 
Research Datalink (CPRD; formerly General Practice Research Database), which is well-116 
validated and used frequently for observational research, is the world’s largest repository of 117 
anonymized longitudinal data from primary care, drawing from over 600 subscribing practices 118 
throughout the UK.15,16 The Optimum Patient Care Research Database (OPCRD) is a quality-119 
controlled primary care research database that contains anonymous routine medical record 120 
data and patient-completed questionnaire data from over 400 practices throughout the UK 121 
caring for approximately a half million patients with asthma.17 Data were available from 122 
January 1990 through April 2012 for the CPRD and through December 2012 for the OPCRD. 123 
 The study was conducted to standards recommended for observational research18 and 124 
is registered with the European Network of Centres for Pharmacoepidemiology and 125 
Pharmacovigilance (ref ENCEPP/SDPP/10483). Use of the data was approved in 2010 by the 126 
Independent Scientific Advisory Committee of the (then) General Practice Research 127 
Database. The OPCRD has been approved by the Trent Multi Centre Research Ethics 128 
Committee for clinical research use, and the protocol for this study was approved by the 129 
Anonymized Data Ethics Protocols and Transparency (ADEPT) committee, the independent 130 
scientific advisory committee for the OPCRD. Further background information is in the online 131 
supplementary material. 132 
Inclusion and exclusion criteria 133 
Inclusion criteria were: a Read code diagnosis of asthma or with ≥2 inhaler prescriptions 134 
including ≥1 for ICS in the previous 12 months (the latter comprise 2% of the study 135 
population10); prescribed a step-up with LABA from ICS monotherapy at 5–12 years of age; 136 
registered in the database for ≥2 sequential years, including 1 baseline year before the date 137 
of therapy step-up (the index date). Exclusion criteria were: cystic fibrosis or any chronic 138 
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respiratory disease other than asthma; receipt of add-on therapy (including combination 139 
inhaler) at any time prior to the index date; treatment with >7 consecutive days oral 140 
corticosteroids (OCS) during the baseline year; multiple step-up therapies on the index date; 141 
≥50% increase or decrease in ICS dose on the index date (the latter ensured that we studied 142 
outcomes of addition of LABA independent of change in ICS).  143 
Study Outcomes 144 
The primary endpoint, previously described,19-21 was overall asthma control (expressed as an 145 
adjusted odds ratio, aOR) and this includes both components of the American Thoracic 146 
Society/European Respiratory Society22 definition of asthma control, i.e. the level of clinical 147 
asthma control (as evidenced here by short acting beta agonist use) and the risk of future 148 
adverse events (as evidenced here by a history of adverse events including hospitalisation, 149 
ED visit and receipt of OCS).  Overall asthma control is defined in table 1. A prescription for 150 
antibiotics in conjunction with a respiratory consultation was included in the definition of an 151 
acute respiratory event (and absence of same in the definitions of asthma control) because in 152 
clinical practice antibiotics may be prescribed for an asthma exacerbation.23-,25 Secondary 153 
outcomes were acute respiratory events, severe exacerbation,26 risk-domain measure of 154 
asthma control (to give insight into risk for future exacerbation) 19-21  and treatment stability 155 
(see table 1 for definitions).  Medication use during the 12 months after the index date was 156 
also compared between cohorts.  Statement re coding for hospitalisation, ER and outpatients. 157 
Calculations of medication use 158 
We calculated the average daily doses of SABA and of ICS during the baseline and outcome 159 
years as the [number of inhalers x doses per inhaler] divided by 365 multiplied by strength (in 160 
µg). For ICS doses we used the beclomethasone dipropionate (BDP)-equivalent doses for the 161 
calculations, thus a 1:1 ratio for budesonide: BDP, 2:1 for fluticasone propionate: BDP, and 162 
2:1 for extrafine beclomethasone (Qvar): BDP. The ICS medication possession ratio (MPR) 163 
was calculated as the number of days coverage of the drug prescribed divided by 365 164 
multiplied by 100 and expressed as <80% (non-adherent) and ≥80% (adherent).27,28 The 165 
separate LABA inhalers that were available during the study period contained salmeterol or 166 
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formoterol; the FDC ICS/LABA inhalers contained fluticasone-salmeterol (Seretide), 167 
budesonide-formoterol (Symbicort), and extrafine beclomethasone-formoterol (Fostair). 168 
Statistical analyses and sample size 169 
Children in the two treatment cohorts (separate ICS+LABA and FDC ICS/LABA) were 170 
matched sequentially 1:1 on the following criteria which were either known to differ at base 171 
line4:year of index date (±3 years), age (exact year), baseline year number of severe 172 
exacerbations (0 or ≥1), prior ICS daily dose (≤150, 151–250, 251–500, or >500 µg/day), and 173 
baseline year mean daily SABA dose (0, 1–200, >200 µg/day). Bespoke software was used 174 
to randomly select unique matched patient pairs when more than one match was possible. 175 
 Data were prepared for analysis by investigating potential outliers, transforming 176 
skewed data (e.g., log transformation), and categorizing heavily skewed data; missing data 177 
were investigated for type and reason for missingness. All matched unadjusted baseline and 178 
outcome data were tabulated using summary statistics and compared using conditional 179 
logistic regression and an intention-to-treat analysis, whereby all children were included in the 180 
outcome year analyses. 181 
The rates of adverse respiratory events and severe exacerbations during the outcome 182 
year were compared using a negative binomial regression model to estimate adjusted ratio 183 
ratios (aRR) and 95% CIs, with FDC ICS/LABA cohort as the reference cohort. General 184 
estimating equations were used to account for the correlation within matched pairs.29 The 185 
model used empirical standard errors for more robust confidence intervals (CIs) and adjusted 186 
for potential baseline confounders.  187 
Conditional logistic regression models were used to estimate adjusted odds ratios 188 
(aOR) and 95% CIs for the dichotomous outcomes, e.g. overall asthma control, with FDC 189 
ICS/LABA as the reference, and adjusted for potential confounding factors.  190 
 For all multivariable models, those variables that were significantly different or showed 191 
a trend towards a difference (P < 0.10) between the treatment cohorts at baseline were 192 
included as potential confounding factors along with any strongly predictive variables. 193 
Potential confounders examined are listed in the online supplementary material (Table S1). 194 
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Variables were examined for collinearity and clinical importance and were then removed in a 195 
backwards stepwise procedure until all confounding variables remaining in the multivariable 196 
model had P < 0.1 (see online supplementary material for further details).  197 
 No prospective power calculation was carried out since our sample size was 198 
determined by the number of eligible children in CPRD and OPCRD. The analyses were 199 
carried out using IBM SPSS Statistics version 21 (SPSS Statistics, IBM, Somers, NY, USA), 200 
SAS version 9.3 (SAS Institute, Marlow, Buckinghamshire, UK), and Microsoft Excel 2007 201 
(Microsoft, Bellevue, WA, USA); statistically significant results were defined as P < 0.05.  202 
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RESULTS 203 
Patients 204 
Overall, 1390 and 3771 children were eligible for the FDC ICS/LABA and separate 205 
ICS+LABA cohorts, respectively (see figure in supplementary file). Ninety seven percent of 206 
children had a diagnosis of asthma and 70% were from OOPCRD.  After matching there were 207 
1330 children in each cohort, of mean age (SD) 9 (2) years, and 59% were male (table 2). The 208 
two cohorts were similar in characteristics apart from the separate ICS+LABA cohort having 209 
higher dose ICS at baseline, higher annualized ICS doseand the LABA step up occurring one 210 
year earlier (i.e. 2005 versus 2006) compared to the FDC cohort, table 2 and table S3.The 211 
cohorts were well-matched for indicators of baseline asthma severity and control table 3.  212 
 213 
Outcomes 214 
Primary outcome 215 
The proportion of children who achieved overall asthma control was 35% before the index 216 
data and 43% afterwards among the FDC cohort and corresponding proportions were 35% 217 
and 37% among the ICS+LABA cohort; the adjusted odds ratio (aOR) for children in the 218 
ICS+LABA cohort achieve control relative to the FDC cohort was 0.77 (0.66–0.91; P = 0.001), 219 
table 3, figure 1.   220 
Secondary outcomes 221 
The rate of acute respiratory events was greater among the ICS+LABA cohort compared to 222 
the FDC group (adjusted rate ratio [aRR] 1.21; 1.04–1.39; P = 0.012; table 3, figure 1).  The 223 
percentage of children with ≥1 severe exacerbations was 13% during the baseline year for 224 
both cohorts and in the outcome year was 7% for the FDC cohort and 9% for the ICS+LABA 225 
cohort; the aRR for severe exacerbations among the children prescribed ICS+LABA relative 226 
to FDC was 1.31 (95% CI; 0.99–1.72; P = 0.056; table 3, figure 1). Relative to the FDC cohort, 227 
children in the ICS+LABA as separates cohort were at reduced  odds for  achieving risk-228 
domain asthma control (aOR 0.74; 0.61–0.89; P = 0.003) and achieving treatment stability 229 
(aOR 0.67; 0.57–0.79; P < 0.001), table 3, figure 1. There were no significant differences 230 
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between cohorts for medication possession ratio being >80% or for severe exacerbations.  In 231 
the follow up year there were 6 hospitalizations for asthma in each cohort (P = 0.99).  There 232 
were 16 children in the FDC cohort and 3 in the separates cohort treated for thrush during the 233 
follow up year (P = 0.008, see on line supplement).  Compared to the baseline year, more 234 
children in the separates cohort (29.9% in baseline year and 19.6% in follow up year) received 235 
treatment with antibiotics during the follow up year than in the FDC cohort (28.6% and 22.5% 236 
respectively, p=0.041).   There was a trend which approached significance for a greater 237 
proportion of the separates cohort to receive oral corticosteroids compared to the FDC cohort 238 
during the follow up year (8.8% versus 6.5%, p=0.084) but no difference in the number with 239 
asthma-related hospital admissions and GP consultations for asthma.  240 
Asthma prescribing during outcome year 241 
Asthma therapy prescribed during the outcome year, as well as changes in therapy, are 242 
summarized in table 4. Children in the FDC cohort typically received one fewer SABA inhaler 243 
in the outcome year (3 versus 4, table 4) compared with the ICS+LABA as separates. Children 244 
in the FDC ICS/LABA cohort were more likely to have an increase in ICS dose compared with 245 
the ICS+LABA as separates (10% vs. 4%; P < 0.001) but no more likely to have LTRA added. 246 
Seventeen percent of children in the ICS+LABA as separates cohort were started on an FDC 247 
during the outcome year. The proportion of children with MPR>80% was 33% in the FDC 248 
cohort and was 31% for the ICS+LABA as separates cohort (aOR 0.87 [0.72–1.06]). During 249 
the outcome year the median daily ICS dose was 219 μg for both cohorts, 231 children in the 250 
separates cohort switched to FDC, 17 in the FDC switched to separates and LTRA treatment 251 
was started in 122 in the FDC cohort and 112 in the separates cohort. 252 
 253 
  Turner et al.  13 
 
 13 
DISCUSSION 254 
The aim of this matched cohort study was to provide evidence to support guidelines 255 
recommending that children receiving LABA as an add-on to ICS treatment should be 256 
prescribed a fixed combination inhaler and not an additional separate LABA inhaler, as 257 
prescribing of separates remains very common in UK clinical practice despite 258 
recommendations .2,3 The main finding was that children prescribed add-on LABA with ICS as 259 
separate inhalers had a 30% greater odds of not having controlled asthma compared with 260 
children prescribed FDC.  Additionally the use of separate inhalers was associated with a 21% 261 
greater exacerbation rate compared with those who received FDC. The fact that 17% of 262 
children in the separate LABA cohort were prescribed an FDC inhaler during the outcome year 263 
suggests that prescribers may be trialing LABA as a separate, but our data suggest that the 264 
trial should be with FDC in the first instance. Our results provide additional evidence that 265 
supports guideline recommendations for LABA to be prescribed as FDC, and not as separate, 266 
inhaler..2,3    267 
Although significant, the improvement in outcomes for those treated with FDC was only 268 
improved by a small degree compared with treatment with separate ICS and LABA inhalers 269 
(figure 1).  We present our results as odds ratios, and the effect size is small when presented 270 
as a likelihood ratio for achieving control (0.9 for the separates cohort compared to the FDC 271 
cohort), or number needed to treat (17 children would require treatment with FDC instead of 272 
separate in order to mean  one child  achieved control).  This small effect may be partly 273 
explained by improvement in all outcomes in both groups as the children became older.  An 274 
additional factor may be that adherence was relatively poor for all participants (22-33%).  275 
Overall, relatively few children prescribed LABA in our study achieved overall asthma control 276 
(35-43%), and whilst this is partly related to the moderate severity of their disease this study 277 
highlights the burden of respiratory morbidity in children with asthma which can be at least 278 
partly improved by FDC prescription in place of ICS and LABA separates, typically one fewer 279 
SABA canister per annum. 280 
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 There is little prior published work comparing outcomes with FDC versus separate 281 
inhalers for children prescribed add-on LABA yet many thousands of children are prescribed 282 
LABA each year. Outcomes were similar with FDC versus separate inhalers for children in two 283 
relatively short double-blind, double-dummy trials,8,9 although one trial did observe a greater 284 
increase in peak expiratory flow in children receiving FDC compared with ICS+LABA as 285 
separates.9 These studies8,9 might have been underpowered to detect differences between 286 
two effective treatments, and additionally it is well-recognized that clinical trials recruit 287 
individuals whose disease is exceptionally stable and whose adherence behavior is not 288 
generalizable to the whole population and this potentially reduces the ability of clinical trials to 289 
detect  a difference in outcome between treatment groups.18 A recent retrospective 290 
observational database study observed that children prescribed FDC inhalers received fewer 291 
acute oral corticosteroid courses and in 2 of the 4 years studied, also less reliever medication 292 
than those prescribed separate inhalers.4  One possible explanation for the findings of Elkout 293 
et al.4 is that the apparent benefit of FDC is due to children receiving separates being at 294 
increased risk for adverse outcomes per se and our previous work confirms that younger 295 
children are more likely to be prescribed separate inhalers10 and are also more likely to have 296 
exacerbations.30 The present study applied a matched cohort analysis and although there 297 
were small differences between cohorts in ICS dose at baseline where any effect would 298 
minimize any benefit of step up to FDC we are able to conclude that the benefit of FDC over 299 
separates is not explained by differences at baseline.   300 
 The use of an FDC ICS/LABA inhaler has several theoretical benefits over two 301 
separate inhalers. The concurrent delivery of a bronchodilator (LABA) may provide a 302 
symptomatic benefit with use of FDC inhalers that promotes inhaler use, and thus improved 303 
adherence with treatment and increased consumption of concomitant ICS.31,32 Other authors 304 
have hypothesized there may be a biochemical synergy between ICS and LABA with their co-305 
deposition in the airways.33,34 Moreover, an important advantage of combining ICS and LABA 306 
in one inhaler is the prevention of LABA use as monotherapy, which carries potential increased 307 
risk of asthma-related mortality and since 2005 is accompanied by a Food and Drug 308 
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Administration (FDA) “black box” warning in the US.35,36 A 2010 FDA recommendation was 309 
that “a FDC product…be used to ensure compliance with concomitant therapy in pediatric and 310 
adolescent patients”.37 Conversely, an advantage of prescribing separate inhalers is the ability 311 
to titrate ICS dose independently of the LABA. 312 
 The assumption of better LABA adherence with use of a single FDC ICS/LABA inhaler 313 
rather than two separate inhalers is generally acknowledged.2 We found no evidence for 314 
improved ICS adherence between cohorts, in terms of refill prescription rates, but the 315 
increased number of children treated for thrush in the FDC compared to separates suggests 316 
increased adherence with ICS in the FDC cohort.  Some retrospective observational studies 317 
find that FDC inhalers are associated with better adherence and refill persistence by both 318 
adults and adolescents with asthma,12-14 but this finding is not seen in all studies. For example, 319 
in one randomized controlled trial (patient ages 16–65 years) where covert electronic 320 
monitoring was used, similar adherence was found with FDC and separate inhaler therapy.38 321 
In a retrospective observational study, and consistent with our findings, Elkout et al.39 found 322 
that MPR was similar for children prescribed separate ICS+LABA inhalers and FDC LABA/ICS 323 
and it is possible that although separate ICS and LABA inhalers are issued with equal 324 
frequency, adherence with ICS is higher compared with LABA separate. Clearly more 325 
research is needed in this area but the limited data from children presented here and from 326 
adults elsewhere38 suggest that FDC is associated with superior outcomes compared with ICS 327 
plus LABA as separates and this difference may be explained by different taking behavior, 328 
e.g. taking more separates when symptomatic. 329 
 Treatment with a “SMART” regimen has never been recommended for children in the 330 
UK, and our study cannot give insight into the potential benefits of this practice.  There is 331 
evidence of reduced exacerbations in children randomized to a “SMART” regimen compared 332 
with FDC40 but this work has not been confirmed elsewhere or incorporated into guidelines to 333 
date.  334 
Antibiotics are not recommended for the treatment of acute asthma excerbations in 335 
any age group, but since antibiotics are commonly prescribed for childhood asthma 336 
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exacerbations23-25 failure to consider antibiotic prescribing will result in missing a large number 337 
of exacerbations.  One study of 60 million asthma exacerbations reported that one in six 338 
pediatric exacerbations were treated with antibiotics, and only 26% of those treated with 339 
antibiotics received corticosteroid treatment (i.e. 12% of all exacerbations)25 and would not be 340 
identified as an exacerbation.       341 
This study has several strengths. We drew on well-maintained and stable datasets 342 
containing medical record information for approximately 15% of children in the UK through 343 
2012. A full baseline year was used for confounder definition, and a full outcome year for 344 
examining asthma-related outcomes to capture infrequent events such as exacerbations and 345 
eliminate the effect of seasonal variations in allergy. A rigorous matching process was used, 346 
which was informed by our previous work that identified differences between children receiving 347 
LABA as separate inhaler or FDC,10 and this resulted in two cohorts with similar demographic 348 
characteristics and baseline indicators of asthma severity and control; adjustments were made 349 
for minor residual confounding. We studied children receiving their first therapy step-up with 350 
add-on LABA, thereby reducing potential effects of declining persistence with therapy over 351 
time.14 352 
Our study has a number of limitations.  First, as in all studies of this nature the patient 353 
outcomes were inferred from prescribing information which brings the benefits of a large 354 
representative sample size but which cannot capture aspects of asthma control such as 355 
nocturnal or exertional symptoms, however we are able to capture use of relieving medication 356 
which is a valid index of asthma control.  We cannot rule out the possibility of undetected 357 
residual confounding in this study, although our matching and analytic methods were designed 358 
to minimize this possibility. Despite matching for index data the FDC cohort was identified one 359 
year after the ICS/LABA cohort, reflecting the later introduction of FDC to clinical practice 360 
compared to separate LABA inhaler, but we do not believe that this difference has substantially 361 
affected the outcome.  Our matching ensured that the children in cohort were prescribed the 362 
same ICS dose (400 µg) but we acknowledge that the separates cohort had received less ICS 363 
over the previous year compared to the FDC cohort (143 versus 164 µg) and do not believe 364 
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that this difference has affected the difference seen between cohorts.  Moreover, as in any 365 
observational study there was the potential for bias, for example, differential prescribing with 366 
regard to add-on LABA inhaler choice that could in turn influence outcomes. Missingness was 367 
present but was equally distributed across the two cohorts, e.g.  only 60% of children had 368 
height and weight data available. The children with the most severe asthma, i.e. maintenance 369 
oral corticosteroids, were excluded from the analysis and our results cannot necessarily be 370 
extrapolated to this very small group of patients.  Children with small changes in ICS dose 371 
than recommended (i.e. <50%) were also excluded from our analysis meaning that our results 372 
cannot be extrapolated to this clinical setting.  We acknowledge that the definition of asthma 373 
used may have resulted in inclusion of children without asthma and exclusion of children with 374 
(unrecognized) asthma, but the aim of this study was to compare outcomes between groups 375 
of children with asthma and not outcomes between groups with and without asthma so the 376 
inclusion criteria for asthma diagnosis are not likely to affect the results. Finally, we used an 377 
intention-to-treat analysis but know that 17% of the ICS+LABA cohort received FDC during 378 
the follow up and this will underestimate the true clinical benefit of FDC over ICS+LABA.    379 
 In concluding, routinely acquired healthcare data are a valuable source for determining 380 
treatment benefits in a real world setting and complement results from clinical trials. Our 381 
results, which are based on data collected from 2660 children, provide evidence that for the 382 
whole population LABA treatment in children should be administered as an FDC and not as a 383 
separate inhaler.  384 
     385 
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Table 1 Definitions of database-derived study secondary outcomes.    Definitions of oral 552 
corticosteroid use and respiratory consultation are provided in the supplement. 553 
Study endpoints 
Primary endpoint 
Overall asthma control.  All of the following: no asthma-related hospital admission; no 
emergency room or outpatient attendance for asthma; no prescription for OCS or antibiotic 
with evidence of respiratory consultation; average daily prescribed dose of ≤200 μg/day 
salbutamol or ≤500 μg/day terbutaline (equivalent to ≤2 puffs daily of reliever medication). 
 
Secondary endpoints (determined over 12 months) 
Acute respiratory events 
Acute course of oral corticosteroids (with associated evidence of a respiratory 
consultation) or asthma-related hospitalization or emergency room attendance or antibiotic 
prescription with evidence of a respiratory consultation. 
Rate of severe exacerbations* 
Acute course of oral corticosteroids (with associated evidence of a respiratory 
consultation) or asthma-related hospitalization or emergency room attendance 
Risk-domain asthma control:  
No asthma-related hospital admission, emergency room attendance, or outpatient 
department attendance, and no prescription for acute course of oral corticosteroids 
with evidence of a respiratory consultation, and no antibiotic prescription with evidence 
of a respiratory consultation. 
Treatment stability:  
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Risk-domain asthma control achieved (see above) and no additional therapy during 
the outcome year as either 
a.  
 554 
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Table 2 Baseline characteristics of children prescribed add-on LABA as FDC ICS/LABA inhaler or separate ICS+LABA inhalers: 555 
matched cohorts 556 
Characteristic 
FDC ICS/LABA 
(n=1330) 
Separate ICS + LABA 
(n=1330) 
p Value for difference 
between cohorts 
Male sex, n (%) 780 (58.6) 779 (58.6) 0.97† 
Age at index date, mean (SD) 9.4 (2.2) 9.4 (2.2) n/a† 
Weight categories‡  
Not obese or overweight (i.e. 
<91th BMI centile) 
571 (42.9) 542 (40.8) 
0.11 
Overweight (i.e. 91–97th BMI 
centile) 
118 (8.9) 111 (8.3) 
Obese (i.e. ≥98th BMI centile) 101 (7.6) 136 (10.2) 
Missing BMI data 540 (40.6) 541 (40.7) 
Recorded comorbidity, n 
(%) 
Rhinitis diagnosis 295 (22.2) 333 (25.0) 0.083 
Eczema diagnosis 664 (49.9) 658 (49.5) 0.81 
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Year of index date, median (IQR) 
2006 (2004–
2008) 2005 (2003–2007) <0.001 
Year since first asthma script, median (IQR)  3 (1–5) 3 (1–6) 0.29 
Median (IQR) annualized daily ICS dose, μg/d¶ 143 (82–247) 164 (99–274) 0.001 
ICS dose prescribed before 
index date, n (%) 
≤150 μg/d 0 (0) 0 (0) 
n/a† 
151–250 μg/d 248 (18.6) 248 (18.6) 
251–500 μg/d 1000 (75.2) 1000 (75.2) 
>500 μg/d 82 (6.2) 82 (6.2) 
Median ICS (IQR) ICS dose at index date (μg/d) 400 [400,400] 400 [400, 400] n/a† 
Mean daily SABA dose, 
n (%)¶ 
0 μg/d 21 (1.6) 21 (1.6) 
n/a† 
≤200 μg/d 652 (49.0) 652 (49.0) 
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>200 μg/d 657 (49.4) 657 (49.4) 
   
    
†Matching variable. 557 
‡ Cut offs for overweight and obese recommended by the Royal College of Paediatrics and Child Health.41 558 
¶The doses of ICS and SABA were averaged over the baseline year using the formula [number of inhalers x doses per inhaler] divided by 365 x 559 
strength (in µg). ICS doses were standardized to equivalence with standard-particle beclomethasone; thus, the actual doses of budesonide were 560 
used, and doses of extrafine beclomethasone and fluticasone were doubled. 561 
BMI, body mass index; CPRD, Clinical Practice Research Datalink; FDC, fixed-dose combination; ICS, inhaled corticosteroid; IQR, interquartile 562 
range; LABA, long-acting β-agonist; n/a, not applicable; OPCRD, Optimum Patient Care Database; SD, standard deviation. 563 
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Table 3 Study endpoints, and their components, during the baseline and outcome years. Negative binomial logistic regression models which 565 
yield adjusted. Unadjusted p values are presented here.  Adjusted Odds Ratio and Rate Ratio with p values are presented in figure one.  566 
Characteristic 
Baseline year Outcome year 
FDC 
ICS/LABA 
(n=1330) 
Separate 
ICS + LABA 
(n=1330) 
p value for 
difference 
between 
groups 
 
FDC 
ICS/LABA 
(n=1330) 
Separate 
ICS + LABA 
(n=1330) 
p value for 
difference 
between 
groups 
during the 
follow up 
years relative 
to baseline 
year without 
adjustment  
Achieve overall asthma control 469 (35.3) 464 (34.7) 0.59 543 (43.1) 495(37.2) 0.001 
Acute respiratory events, mean (SD) 0.49 (0.84) 0.54 (0.92) 0.084 0.32 (0.71) 0.39 (0.75) 0.011 
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Acute respiratory events, 
n (%) 
0 883 (66.4) 857 (64.4) 
0.21 
1031 (77.5) 966 (72.6) 0.003 
1 300 (22.6) 316 (23.8) 217 (16.3) 256 (19.2) 
≥2 147 (11.1) 157 (11.8) 82 (6.2) 108 (8.1) 
Severe exacerbations, n 
(%) 
0 1157 (87.0) 1157 (87.0) 
0.54† 
1237 (93.0) 1205 (90.6) 0.056 
1 136 (10.2) 131 (9.8) 68 (5.1) 98 (7.4) 
≥2 37 (2.8) 42 (3.2) 25 (1.9) 27 (2.0) 
Achieved risk-domain 
asthma control, n (%) 
 846(65.1) 
 
820480 (63.9) 
0.21 
999 (77.4) 973 (72.5) 
0.003 
Achieved treatment stability, 
n (%) 
 
n/a n/a n/a 
842 (65.6)  947 (56.9)     
<0.001 
†Matching variable. Note: severe exacerbations were matched as 0 or ≥1. 567 
FDC, fixed-dose combination; GP, general practice; ICS, inhaled corticosteroid; IQR, interquartile range; LABA, long-acting β-agonist; n/a, not 568 
applicable; SABA, short-acting β-agonist.569 
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Table 4 Asthma therapy prescribed during the outcome year 570 
Outcome 
FDC ICS/LABA 
(n=1330) 
Separate ICS + 
LABA 
(n=1330) 
p value for 
difference 
between 
groups 
SABA inhalers, median (IQR) 3 (2–6) 4 (2–7) <0.001 
Change in therapy (any time), n (%) 244 (18.3) 326 (24.5) <0.001 
Increase in ICS dose ≥50% (any time) 133 (10.0) 58 (4.4) <0.001 
†The doses of ICS and SABA were averaged over the outcome year using the formula 571 
[number of inhalers x doses per inhaler] divided by 365 x strength (in µg). SABA doses were 572 
converted to puffs using the formula 100 µg = 1 puff. The doses of ICS were standardized to 573 
equivalence with standard-particle beclomethasone; thus, the actual doses of budesonide 574 
were used, and doses of extrafine beclomethasone and fluticasone were doubled. 575 
FDC, fixed-dose combination; ICS, inhaled corticosteroid; IQR, interquartile range; LABA, 576 
long-acting β-agonist; LTRA, leukotriene receptor antagonist; n/a, not applicable (comparison 577 
not possible because of 0 or low number); SABA, short-acting β2-agonist. 578 
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 580 
FIGURE LEGEND 581 
 582 
 583 
 584 
Figure 1. Adjusted asthma-related outcome measures comparing matched treatment 585 
cohorts during 1 outcome year. adjOR/adjRR, adjusted odds ratio/rate ratio; FDC, fixed-dose 586 
combination; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; SABA, short-acting 587 
β2-agonist 588 
*Adjusted for nonsteroidal anti-inflammatory drugs 589 
†Adjusted for baseline acute respiratory events and paracetamol prescription 590 
‡Adjusted for baseline severe exacerbations and number of asthma and non-asthma 591 
consultations 592 
§Adjusted for paracetamol prescription  593 
¶Adjusted for data source 594 
 595 
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